A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatitis C Infected Patients

Trial Profile

A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatitis C Infected Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs JNJ 56914845 (Primary) ; Simeprevir (Primary) ; TMC 647055 (Primary) ; Ribavirin; Ritonavir; Ritonavir
  • Indications Hepatitis C
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 10 Feb 2017 Results published in the BMC Gastroenterology
    • 16 Mar 2015 Results published in Medivir AB media release.
    • 25 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top